- Home
- CREV vs ACXP Comparison
CREV vs ACXP Comparison
Compare CREV & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CREV
- ACXP
- Stock Information
- Founded
- CREV 2007
- ACXP 2017
- Country
- CREV Australia
- ACXP United States
- Employees
- CREV N/A
- ACXP N/A
- Industry
- CREV
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- CREV
- ACXP Health Care
- Exchange
- CREV Nasdaq
- ACXP Nasdaq
- Market Cap
- CREV 7.0M
- ACXP 6.8M
- IPO Year
- CREV N/A
- ACXP 2021
- Fundamental
- Price
- CREV $5.52
- ACXP $6.57
- Analyst Decision
- CREV
- ACXP Strong Buy
- Analyst Count
- CREV 0
- ACXP 3
- Target Price
- CREV N/A
- ACXP $143.67
- AVG Volume (30 Days)
- CREV 1.4M
- ACXP 1.6M
- Earning Date
- CREV 05-14-2025
- ACXP 11-12-2025
- Dividend Yield
- CREV N/A
- ACXP N/A
- EPS Growth
- CREV N/A
- ACXP N/A
- EPS
- CREV N/A
- ACXP N/A
- Revenue
- CREV $47,677,475.00
- ACXP N/A
- Revenue This Year
- CREV $40.32
- ACXP N/A
- Revenue Next Year
- CREV N/A
- ACXP N/A
- P/E Ratio
- CREV N/A
- ACXP N/A
- Revenue Growth
- CREV 86.77
- ACXP N/A
- 52 Week Low
- CREV $2.00
- ACXP $3.80
- 52 Week High
- CREV $12.75
- ACXP $39.20
- Technical
- Relative Strength Index (RSI)
- CREV 67.65
- ACXP 58.01
- Support Level
- CREV $4.71
- ACXP $6.31
- Resistance Level
- CREV $5.62
- ACXP $6.80
- Average True Range (ATR)
- CREV 0.47
- ACXP 0.59
- MACD
- CREV 0.14
- ACXP -0.11
- Stochastic Oscillator
- CREV 94.23
- ACXP 17.11
About CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.